loading

Adial Pharmaceuticals Inc (ADIL) 最新ニュース

pulisher
Feb 21, 2025

Adial Pharmaceuticals' Chief Medical Officer Presents AD04 at the Scientific Federation 7th World Congress on Nursing & Healthcare - ACCESS Newswire

Feb 21, 2025
pulisher
Feb 20, 2025

Adial Pharmaceuticals Announces Approval to Commence Landmark ONWARD(TM) Pivotal Phase 3 Trial in Sweden and Estonia - ACCESS Newswire

Feb 20, 2025
pulisher
Feb 19, 2025

Adial Pharmaceuticals Granted New U.S. Patent Expanding - GlobeNewswire

Feb 19, 2025
pulisher
Feb 19, 2025

Adial Pharmaceuticals Granted New U.S. Patent On Method To Identify Genetic Markers In Alcohol or Opioid-Related Disorders - Marketscreener.com

Feb 19, 2025
pulisher
Feb 19, 2025

Adial Granted New U.S. Patent Expanding Genetic-Based Approach For Addiction Treatment - Nasdaq

Feb 19, 2025
pulisher
Feb 19, 2025

Adial Pharmaceuticals secures patent for genetic addiction treatment - Investing.com

Feb 19, 2025
pulisher
Feb 19, 2025

This Groundbreaking Patent Could Transform How We Treat AddictionHere's Why Genetics Matter - StockTitan

Feb 19, 2025
pulisher
Feb 16, 2025

Adial Pharmaceuticals Receives Approval to Commence Phase 3 Trial in Bulgaria - ACCESS Newswire

Feb 16, 2025
pulisher
Feb 13, 2025

Adial Is Filling The Gap In Alcohol Use Disorder Treatment With Repurposed Drug - News & Insights

Feb 13, 2025
pulisher
Feb 13, 2025

Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Sees Significant Growth in Short Interest - Defense World

Feb 13, 2025
pulisher
Feb 12, 2025

Adial Pharmaceuticals Awarded U.S. Patent For Genotype-Specific Treatment Of Opioid Disorders - Nasdaq

Feb 12, 2025
pulisher
Feb 12, 2025

Adial Pharmaceuticals Awarded New U.S. Patent Covering Genotype-Specific Treatment of Opioid-Related Disorders - The Manila Times

Feb 12, 2025
pulisher
Feb 12, 2025

Adial Pharmaceuticals Secures Patent for Genetically Targeted Treatment Methods in Addiction Therapy - Nasdaq

Feb 12, 2025
pulisher
Feb 12, 2025

Adial Pharmaceuticals secures new patent for addiction treatment - Investing.com

Feb 12, 2025
pulisher
Feb 12, 2025

Revolutionary Patent Win: Adial's DNA-Guided Solution Takes On $35B Addiction Crisis - StockTitan

Feb 12, 2025
pulisher
Feb 12, 2025

EXCLUSIVE: Adial Pharmaceuticals Secures New US Patent Covering Genotype-Specific Treatment of Opioid-Related Disorders - Yahoo Finance

Feb 12, 2025
pulisher
Feb 11, 2025

Reddit (RDDT) Q4 Earnings: What To Expect - The Globe and Mail

Feb 11, 2025
pulisher
Feb 07, 2025

Adial Pharmaceuticals Schedules Business Update Conference Call to Discuss Planned Acquisition of Purnovate and other Recent Developments - ACCESS Newswire

Feb 07, 2025
pulisher
Feb 04, 2025

Adial Pharmaceuticals Submits Clinical Trial Applications in Six Additional European Countries - ACCESS Newswire

Feb 04, 2025
pulisher
Feb 03, 2025

Clinical Trials News Live Feed - StockTitan

Feb 03, 2025
pulisher
Jan 31, 2025

Adial completes key study for alcohol disorder drug - MSN

Jan 31, 2025
pulisher
Jan 29, 2025

Adial Pharmaceuticals Receives European Medicines Agency (EMA) Agreement on the Pediatric Investigation Plan (PIP) for AD04 in Alcohol Use Disorder - ACCESS Newswire

Jan 29, 2025
pulisher
Jan 29, 2025

ADILAdial Pharmaceuticals, Inc Latest Stock News & Market Updates - StockTitan

Jan 29, 2025
pulisher
Jan 29, 2025

Adial Pharmaceuticals Announces Positive Clinical Study Results from the AD04-103 Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder - The Manila Times

Jan 29, 2025
pulisher
Jan 29, 2025

Adial completes key study for alcohol disorder drug By Investing.com - Investing.com UK

Jan 29, 2025
pulisher
Jan 29, 2025

Adial Pharmaceuticals Announces Positive Clinical Study - GlobeNewswire

Jan 29, 2025
pulisher
Jan 29, 2025

Game-Changing Alcohol Addiction Treatment Clears Critical FDA Hurdle - StockTitan

Jan 29, 2025
pulisher
Jan 29, 2025

EXCLUSIVE: Adial Pharmaceuticals Reveals Positive Pharmacokinetics Study Results Of AD04 For Alcohol Use Disorder - Benzinga

Jan 29, 2025
pulisher
Jan 29, 2025

Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Short Interest Down 60.8% in January - Defense World

Jan 29, 2025
pulisher
Jan 28, 2025

Adial Pharma stock hits 52-week low at $0.72 amid market challenges - Investing.com Nigeria

Jan 28, 2025
pulisher
Jan 27, 2025

Adial Pharmaceuticals Announces Appointment of Alex Lugovoy as Head of Strategy - ACCESS Newswire

Jan 27, 2025
pulisher
Jan 20, 2025

Why Bitcoin-Linked MicroStrategy Along With Adial Pharmaceuticals, Alpine Immune Sciences, Marin Software, And Tesla Are On Investors' Radars Today - MSN

Jan 20, 2025
pulisher
Jan 18, 2025

Adial Pharmaceuticals to Commence Business Development Meetings - Defense World

Jan 18, 2025
pulisher
Jan 16, 2025

Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Short Interest Update - Defense World

Jan 16, 2025
pulisher
Jan 13, 2025

Adial Pharmaceuticals Focuses on Strategic Growth Initiatives - TipRanks

Jan 13, 2025
pulisher
Jan 08, 2025

Adial Pharmaceuticals Highlights AD04 for Alcohol Use Disorder - TipRanks

Jan 08, 2025
pulisher
Jan 02, 2025

Alcohol Use Disorder Treatment Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Epidemiology, Therapies, Treatment, Companies by DelveInsight - Barchart

Jan 02, 2025
pulisher
Dec 30, 2024

Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Short Interest Up 16.4% in December - Defense World

Dec 30, 2024
pulisher
Dec 20, 2024

Adial Pharmaceuticals (NASDAQ:ADIL) Stock Quotes, Forecast and News Summary - Benzinga

Dec 20, 2024
pulisher
Dec 18, 2024

Adial Pharmaceuticals’ New Purchase Agreement with Alumni Capital - TipRanks

Dec 18, 2024
pulisher
Dec 13, 2024

Short Interest in Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Drops By 71.7% - Defense World

Dec 13, 2024
pulisher
Dec 11, 2024

Alcohol Use Disorder Market Set for Remarkable Growth During the Study Period (2020–2034) | DelveInsight - GlobeNewswire Inc.

Dec 11, 2024
pulisher
Dec 07, 2024

Adial Pharmaceuticals revises CEO's compensation package By Investing.com - Investing.com South Africa

Dec 07, 2024
pulisher
Dec 07, 2024

Adial Pharmaceuticals revises CEO's compensation package - Investing.com India

Dec 07, 2024
$33.42
price up icon 0.27%
$81.06
price down icon 3.05%
$361.10
price down icon 1.70%
$22.12
price down icon 4.08%
biotechnology ONC
$255.37
price up icon 4.57%
$120.01
price up icon 1.81%
大文字化:     |  ボリューム (24 時間):